Running Point Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Running Point Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$32.8K	–	151
2022 Q4	$32.8K	Hold	400	–	–	0.02%	173
2022 Q3	$38K	Hold	400	–	–	0.03%	161
2022 Q2	$78K	Hold	400	–	–	0.05%	145
2022 Q1	$93K	Buy	+400	New	+$127K	0.05%	141

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Running Point Capital Advisors's ATRA Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 400 shares — an estimated $32.8K sold.

Running Point Capital Advisors first reported a position in ATRA in Q1 2022 and held it in 4 quarters. The position peaked at $93K in Q1 2022. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

Running Point Capital Advisors reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
Running Point Capital Advisors sold 400 Atara Biotherapeutics shares in Q1 2023, an estimated $32.8K.
Running Point Capital Advisors first reported a position in Atara Biotherapeutics in Q1 2022 and held it in 4 quarters.
Running Point Capital Advisors's Atara Biotherapeutics position peaked at $93K in Q1 2022.
125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.